Seeking Alpha

More on Teva (TEVA +0.1%) Q2: net profit rises to $863M from $576M, due to the launch of four...

More on Teva (TEVA +0.1%) Q2: net profit rises to $863M from $576M, due to the launch of four new generic drugs in the U.S. and an increase in sales of branded treatments. Affirms FY outlook for adjusted EPS of $5.30-$5.40 vs. consensus of $5.37 and revenue of $20-$21B vs. $20.58B. U.S. sales +28% to $2.5B, European sales unchanged at $1.5B.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|